Observational studyBMC cancer2025
Exploring the role of tumor to background parenchymal ratio of the [18F]FLT PET/CT measures in determining response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography computed tomography ([18F]FLT PET/CT) in predicting locally advanced breast cancer response to neoadjuvant chemotherapy (NAC), focusing on the role of tumor to background parenchymal ratio (TBR) of the standardized uptake value (SUV) ratios.
methodsThis retrospective analysis utilized prospectively collected data from the multicenter ACRIN 6688 observational trial. It used a dataset of 90 patients from 17 centers with confirmed breast cancer who planned to receive NAC followed by surgery as part of their treatment. Three [18F]FLT PET/CTs were scheduled for each participant at three time points to obtain serial tumor dimensions and TBR values of SUV ratios: before therapy initiation, after completion of the first cycle, and after the termination of chemotherapy.
resultsTumor size, TBRmean, and TBRmax all showed poor diagnostic performance in predicting pathological response in all three scans, with the highest AUC of 0.682. The combined model of PET and CT parameters exhibited the best diagnostic performance, significantly improving the diagnostic values of the first and third PET/CT scans, with AUCs of 0.731 and 0.833 for each scan and 0.875 for their percentage change. The mid-NAC scan did not seem to show any considerable diagnostic value in either of the models, with the highest AUC being 0.626.
conclusionThe combined model, having both tumor size and uptake values as its components, performed well in predicting the tumor's pathological response to chemotherapy, particularly when compared to each component's performance alone, which suggests the complementary role of functional (i.e., TBR) and anatomical (i.e., size) parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.